Black Titan Corp (NASDAQ:BTTC) Short Interest Down 94.5% in August

Black Titan Corp (NASDAQ:BTTC) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 21,671 shares, a decline of 94.5% from the August 15th total of 395,561 shares. Based on an average trading volume of 3,966,225 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.4% of the company’s stock are sold short.

Institutional Trading of Black Titan

Hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC purchased a new position in Black Titan during the fourth quarter worth about $840,000. Marex Group plc acquired a new position in Black Titan during the 4th quarter worth approximately $84,000. HRT Financial LP acquired a new position in Black Titan during the 4th quarter worth approximately $28,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Black Titan during the 4th quarter worth approximately $26,000.

Black Titan Stock Down 0.9%

NASDAQ BTTC traded down $0.00 on Friday, hitting $0.36. 70,025 shares of the stock were exchanged, compared to its average volume of 2,336,066. Black Titan has a fifty-two week low of $0.35 and a fifty-two week high of $39.00. The company has a 50-day moving average price of $0.67 and a 200-day moving average price of $1.02. The company has a quick ratio of 4.62, a current ratio of 4.62 and a debt-to-equity ratio of 0.06. The company has a market cap of $3.91 million, a PE ratio of -0.12 and a beta of 1.17.

Black Titan (NASDAQ:BTTC) last announced its quarterly earnings data on Friday, June 12th. The company reported ($0.22) earnings per share for the quarter. The firm had revenue of $0.59 million for the quarter.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.